News

TRACK ALS Succeeds in Measuring Brain Inflammation Using a PET Scan and Biomarker

Researchers have succeeded in using an imaging technique to record changes and inflammation in the brain of a person with amyotrophic lateral sclerosis (ALS), using a potential biomarker of inflammation. The research, conducted at  The Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital, is part of the  TRACK ALS project to identify imaging markers of ALS, so…

Molecular Stethoscope Working to Validate a Diagnostic Test for ALS and Other Diseases

Molecular Stethoscope, Inc., announced it is working with 23 U.S. academic and medical institutions to further validate its blood-based early diagnostic and disease monitoring tests for hard-to-detect conditions, including amyotrophic lateral sclerosis (ALS) . The San Diego, California-based, company has developed proprietary technology that uses circulating cell-free RNA (ribonucleic acid) in the blood to…

Mobile Laptop System Helps ALS Patients and Others with Limited Mobility Communicate by Eye Movement

Researchers created a mobile cart device allowing people to communicate via laptops by eye movement alone. The device was designed with severely disabled tetraplegic patients in mind, but it may also help those with decreased upper extremity and hand function, like that caused by amyotrophic lateral sclerosis (ALS), to more easily work with a computer. Shannon…

AB Science Reports Positive Interim Results in Phase 3 Trial of Masitinib as an ALS Therapy

AB Science announced that its Phase 2/3 clinical trial evaluating masitinib, the company’s lead compound to treat amyotrophic lateral sclerosis (ALS) patients, has met its primary objective. The ongoing study is currently recruiting participants and expects to finish in June 2017. “The positive outcome of this study in ALS is a significant milestone…

Neuraltus Pharmaceuticals Readies Second Phase 2 Study of Potential ALS Therapy

Neuraltus Pharmaceuticals announced that it will initiate a second Phase 2 clinical trial of its investigational drug candidate NP001 for the treatment of amyotrophic lateral sclerosis (ALS), with the intent of confirming positive earlier findings in patients with elevated levels of baseline inflammation and further evaluating the drug’s efficacy. Inflammation is thought to be a…